Introduction {#s1}
============

Malaria remains the primary cause of death in children in sub-Saharan Africa despite the existence of tools such as antimalarial drugs, insecticide treated bet nets, and indoor residual spraying. It is estimated that malaria causes between 300 and 500 million clinical cases and 700,000 to 1.6 million deaths each year [@pone.0001563-World1]. An effective malaria vaccine is a much needed tool to combat this disease. With the international effort to develop a malaria vaccine, several malaria vaccine candidates have reached the stage of clinical testing in malaria exposed populations. Apical membrane antigen-1 (AMA1) is a surface protein expressed during the asexual blood stage of *P. falciparum,* and is a leading vaccine candidate, with several formulations being tested in malaria endemic areas in Africa [@pone.0001563-Girard1], [@pone.0001563-Epstein1]. Preclinical studies have shown that vaccination with AMA1 induces antibodies and protection against homologous parasite challenge in both rodent and monkey models of malaria infection [@pone.0001563-Collins1], [@pone.0001563-Crewther1], [@pone.0001563-Narum1], [@pone.0001563-Kennedy1], [@pone.0001563-Stowers1].

The AMA1-Combination 1 (C1) vaccine used in this study contains an equal mixture of the correctly folded ectodomain portion of recombinant AMA1 from two different clones of *P. falciparum*, FVO and 3D7. The combination vaccine was chosen because of sequence polymorphism of the AMA1 gene and the strain specific antibody response to recombinant AMA1 [@pone.0001563-Kocken1], [@pone.0001563-Cortes1]. It is hoped that the inclusion of more than one polymorphic protein will induce broader protection against infection with diverse strains of parasites. Phase 1 studies in malaria naïve adults in the US and in semi-immune adults in Mali have shown that the vaccine is safe and immunogenic at a dose of 80 µg [@pone.0001563-Malkin1], [@pone.0001563-Dicko1]. Based on these results, a Phase 1 clinical trial of this vaccine in children was initiated in a malaria-endemic setting in Donéguébougou in Mali, West Africa.

Methods {#s2}
=======

This was a dose-escalating randomized double blind clinical trial designed to assess the safety and immunogenicity of the blood stage malaria vaccine candidate AMA1-C1, adjuvanted with Alhydrogel®. The protocol for this trial and supporting CONSORT checklist are available as supporting information; see [Checklist S1](#pone.0001563.s001){ref-type="supplementary-material"} and [Protocol S1](#pone.0001563.s002){ref-type="supplementary-material"}.

Participants {#s2a}
------------

Participants were healthy children available for the duration of the trial (52 weeks) aged 2 to 3 years old living in the village of Donéguébougou, a village with high seasonal malaria transmission occurring from July to November [@pone.0001563-Dicko2]. Exclusion criteria included recent or current participation in another investigational vaccine or drug trial, history of severe allergic reaction or asthma, known immunodeficiency, recent use of systemic corticosteroids or immunosuppressive drugs, recent receipt of a licensed vaccine or blood transfusion, history of splenectomy, previous receipt of an investigational malaria vaccine or *Hemophilus influenza B* vaccine, known thrombocytopenia or bleeding disorder, abnormal screening laboratories (alanine aminotransferase (ALT) \>62 U/L, serum creatinine \>61 mmol/L, hemoglobin \<8.5 g/dL, absolute leukocyte count \<3000/mm^3^ or \>14,500/mm^3^, absolute lymphocyte count \<1000/mm^3^, or platelet count \<120,000/mm^3^), and any other clinically significant disease or condition which might confound the interpretation of study results.

Ethics {#s2b}
------

Community consent was obtained at a meeting with village leaders, heads of families, and other community members prior to the start of the study. Individual informed consent was then obtained after oral translation of the consent form into the local language. Understanding of the contents of the consent was confirmed by means of a multiple choice questionnaire. Parents or guardians unable to read placed an imprint of his/her finger in place of a signature; an independent witness also signed all consent forms. The study was conducted under a protocol reviewed and approved by the Institutional Review Board of the National Institute of Allergy and Infectious Disease (NIAID), and by the Ethics Committee of the Faculty of Medicine, Pharmacy and Dentistry, University of Bamako. The study was submitted to the U.S. Food and Drug Administration for review as part of Investigational New Drug application BB-IND\#10944. The study was monitored for regulatory compliance and data quality by the Regulatory Compliance and Human Subjects Protection Branch of NIAID and the Initiative for Vaccine Research of WHO. The NIAID Data Safety Monitoring Board (DSMB) and /or local medical monitor reviewed safety data prior to next vaccination and dose escalation.

Interventions {#s2c}
-------------

Both recombinant cGMP AMA1-FVO and AMA1-3D7 are 62 kDa proteins consisting of amino acids 25 through 545 of the published sequences of each line\'s AMA1 gene (GenBank accession number AJ277646 for FVO and accession number U65407 for 3D7). Protein production and vaccine formulation are described in detail elsewhere [@pone.0001563-Kennedy1]. AMA1-C1/Alhydrogel® malaria vaccine was supplied as a slightly turbid suspension in single-dose vials. Each 2.0 mL vial contains a single dose, of which 0.5 mL is the intended volume to be injected. Half mL of vaccine contains about 424 µg of aluminum (Alhydrogel®, HCI Biosector, Denmark) per dose onto which either 20 µg or 80 µg of recombinant AMA1-C1 has been bound. The product conforms to established requirements for endotoxin, sterility, and general safety. The AMA1-C1/Alhydrogel® research products for this protocol were supplied by the Pharmaceutical Development Section, Pharmacy Department, Clinical Center of National Institutes of Health, where the AMA1-C1/Alhydrogel® vaccine was formulated and vialed. Both the AMA1-C1/Alhydrogel® and Hiberix® (GlaxoSmithKline, Uxbridge, UK) vaccines were transported and stored at 0.5°C to 9°C; temperature recording devices accompanied the vaccines at all times to ensure storage temperature limits were not violated.

Hiberix® is a noninfectious vaccine containing purified capsular polysaccharide of *Haemophilus influenzae* type b (Hib) covalently bound to tetanus toxoid. Hiberix® is supplied as a white lyophilized pellet for reconstitution with sterile saline solution 0.9%. Each 0.5 mL dose contains 10 µg of purified polysaccharide covalently bound to approximately 30 µg of tetanus toxoid. Hiberix® meets the World Health Organization requirements for the manufacture of biological substances and Hib conjugate vaccines. Both vaccines were administered IM in the thigh muscles on Days 0 and 28, in alternating legs.

Outcomes: Safety and Tolerability {#s2d}
---------------------------------

Local and systemic adverse events were recorded and graded by severity and relationship to vaccine. Volunteers remained in the study clinic for at least 30 minutes after each immunization to evaluate for immediate adverse reactions. Follow up visits were scheduled for Days 1, 2, 3, 7, and 14 after each vaccination, and at study weeks 12, 22, 30, 42, and 52. Solicited injection site reactions were pain, erythema, and swelling; solicited general adverse events were fever, headache, nausea, malaise, myalgia, arthralgia, urticaria, drowsiness, irritability, and loss of appetite. Investigators also recorded any other adverse events which occurred during the follow up period. Injection site erythema, swelling, and induration were graded as follows: 0 = absent, 1 = 0--20 mm, 2 = \>20--50 mm, 3 = \>50 mm. Fever (axillary) was graded as 0 = \<37.5°C, 1 = 37.6--38°C, 2 = \>38--39°C, and 3 = \>39°C. Pain and solicited adverse events other than fever and urticaria were graded as follows: 0 = absent/none, 1 = easily tolerated, 2 = interferes with daily activity, 3 = prevents daily activity. Non-solicited adverse events were graded as 0 = none, 1 = no effect on activities of daily living, 2 = partial limitation in activities of daily living, or minimal intervention required, 3 = activities of daily living limited to \<50% of baseline, or medical evaluation with intervention required. Hematological (Hb, WBC, and platelets) and biochemical (ALT, and creatinine), laboratory parameters were measured at screening, on days of immunization, and on Days 3 and 14 after each vaccination. Hematology was also performed on Day 7 after each vaccination and at weeks 12, 22, 30, 42, and 52. Serious adverse events (SAEs) were defined as any adverse event resulting in death, life threatening, requiring hospitalization, resulting in disability or incapacity, or any other event which required intervention to prevent such outcomes.

Outcomes: Immunogenicity {#s2e}
------------------------

Antibody responses to the AMA1 antigens were measured in plasma by enzyme linked immunosorbent assay (ELISA) at Days 0, 14, 42, 98 and 154. The ELISA technique used was described previously [@pone.0001563-Malkin1]. A human anti-AMA1 standard plasma was made using a pool of plasma from 3 individuals receiving AMA1-C1 immunization in a US vaccine trial (manuscript in preparation). The standard pool was assigned 460.9 ELISA units on AMA1-FVO and 578.0 units on AMA1-3D7.The minimal detection level of this assay was 28 ELISA units and all data less than 28 ELISA units were assigned a value of 14 units for statistical analysis.

Sample size {#s2f}
-----------

Sample size for the Phase 1 part of the study was based on safety outcomes. Group sizes of 10 provide an 80% likelihood of detecting adverse events that occur with a frequency of 15%. An extra two subjects per group were included in case of loss to follow up.

Randomization {#s2g}
-------------

Participants in the two treatment cohorts (20 µg AMA1-C1/Alhydrogel and 80 µg AMA1-C1/Alhydrogel) were randomized in a 2∶1 ratio to receive either the study vaccine or the control (Hiberix®). Randomization codes were created by the study statistician, and randomization occurred at the time of first vaccination. A copy of the randomization code was provided to the pharmacist who used coded labels for the vaccines, and to the medical monitor and DSMB.

Blinding {#s2h}
--------

The study was double blinded, with both participants and investigators unaware of treatment assignment until completion of the study. Since the appearance of the vaccines was slightly different, opaque tape was placed over the syringe so that investigators were unable to see the contents. Unblinding of the investigators occurred after adverse event and immunologic databases to Day 154 were cleaned and finalized.

Statistical methods {#s2i}
-------------------

Exact Jonckheere--Terpstra (J-T) tests were performed to examine dose-response relationships for adverse events, according to dose of AMA1-C1 vaccine (control, low dose, and high dose) for each category of AE and total number of AEs. For each AE category tested, each subject was defined as having a response of no AE, grade 1 AE, grade 2 AE, grade 3 AE or SAE based on the subjects highest grade of AE in that category. In order to maintain a low threshold for detecting safety concerns no correction was made for multiple comparisons. For each subject, the arithmetic average of the FVO and 3D7 ELISA responses at each day was used as that subject\'s AMA1-C1 antibody response for that day. The primary immunological outcome in this trial was the difference in AMA1-C1 antibody response between Day 42 and Day 0. Dose response was tested by exact J-T test. Similar J-T tests were performed for other vaccine days using the differences in antibody response between other time points (Days 14, 98 and 154) and Day 0. All ELISA data for two subjects were excluded from the antibody response analyses, because there appeared to be specimen mishandling in those two cases. The decision to exclude these subjects was made before unblinding. No other subjects were excluded from the immunogenicity analysis, and those two subjects were included in all safety analyses. The concordance between log transformed antibody levels against AMA1-FVO and AMA1-3D7 was measured with random marginal agreement coefficients with squared difference as suggested in Fay (2005) [@pone.0001563-Fay1].

Results {#s3}
=======

Participant Flow and Baseline Data {#s3a}
----------------------------------

Seventy seven children were screened for inclusion in the study, of whom 36 (19 males and 17 females) were enrolled ([Figure 1](#pone-0001563-g001){ref-type="fig"}). Reasons for exclusion were concurrent illness (n = 13), positive serology for chronic hepatitis B or C (n = 8), hemoglobin \<8.5 g/dL and/or malnutrition (n = 6), other abnormal screening laboratory tests (n = 7), age outside the specified range (n = 6), and one subject was eligible but not enrolled as enrollment was complete. The first cohort (12 subjects receiving 20 µg AMA1-C1/Alhydrogel and 6 subjects receiving Hiberix®) was vaccinated on March 16, 2006 and the second cohort (12 subjects receiving 80 µg AMA1-C1/Alhydrogel and 6 receiving Hiberix®) was vaccinated about 2 weeks later. The second vaccination of the 2^nd^ cohort was completed about 2 months prior to the start of malaria transmission season. Three subjects (1 in Hiberix® group and 2 in the 80 µg dose group) did not receive the second vaccination due to acute Hepatitis A infection. All the participants completed followed up to Day 154.

![CONSORT Flow Chart.](pone.0001563.g001){#pone-0001563-g001}

Safety {#s3b}
------

Both doses of the AMA1-C1 vaccine were well tolerated ([Table 1](#pone-0001563-t001){ref-type="table"}). A total of 9 adverse events that were considered definitely, probably or possibly related to the vaccination occurred in 7 subjects who received the AMA1-C1 vaccine. Most (5/9) were local injection site reactions. All were mild to moderate in severity and resolved within 4 days except one case of elevated ALT that persisted through the end of the follow up period. This subject was enrolled with ALT of 47.3 U/L (near the upper limit of normal range 49.6 U/L). His ALT increased to 72.8 U/L at Day 3, decreased to 59.4 U/L on Day 14 but remained slightly above the normal range throughout the follow up period. Tests for hepatitis A, B and C in this individual were repeatedly negative. As no apparent etiology was found it was classified as possibly related to the vaccination. There was no significant relationship between AMA1-C1 dose and either severity of AE overall or in any specific category of AEs. There were no severe or serious adverse event deemed related to the vaccination in any group. Three serious adverse events (one in each group) were reported. All were related to acute viral Hepatitis A (two hospitalizations and one Grade 4 elevation of ALT protocol defined as an SAE) and were considered unrelated to the vaccination.

10.1371/journal.pone.0001563.t001

###### Local injection site, systemic and laboratory adverse events judged definitely, probably, or possibly related to vaccine after vaccination with the AMA1-C1/Alhydrogel® or Hiberix® vaccines.

![](pone.0001563.t001){#pone-0001563-t001-1}

                    Vaccination \#1   Vaccination \#2   Vaccinations \#1 and \#2                      
  ---------------- ----------------- ----------------- -------------------------- --- --- --- --- --- ---
  **Local**                                                                                           
  Pain                     1                 1                     1               0   1   0   1   2   1
  Swelling                 1                 0                     0               1   0   0   2   0   0
  Erythema                 1                 0                     1               0   0   0   1   0   1
  **Systemic**                                                                                        
  Fever                    0                 0                     1               1   0   0   1   0   1
  Vomiting                 0                 0                     1               0   0   0   0   0   1
  Anorexia                 0                 0                     1               0   0   0   0   0   1
  Drowsiness               0                 0                     1               0   0   0   0   0   1
  **Laboratory**                                                                                      
  Elevated WBC             1                 0                     0               0   0   1   1   0   1
  Elevated ALT             1                 0                     0               0   0   0   1   0   0

IgG responses to AMA1-3D7 and AMA1-FVO {#s3c}
--------------------------------------

Antibody levels against AMA1-3D7 and AMA1-FVO were measured by ELISA at Day 0 prior to vaccination, Days 14, 42, 98 and 154. Data for two subjects (one in the Hiberix® group and another in the 80 µg AMA1-C1 dose group) were excluded because of a labeling error on study Day 42. Of the 34 subjects considered for the immunology analysis, pre-existing antibodies to AMA1-FVO and AMA1-3D7 were detectable in 14 (5 in the Hiberix® group, 4 in the 20 µg dose group and 5 in the 80 µg dose group) and 17 (7 in the Hiberix® group, 4 in the 20 µg dose group and 6 in the 80 µg dose group) respectively. Three subjects (two in the Hiberix® group and one in the 20 µg dose group) had high antibody levels (greater than 1000 units) prior to vaccination.

Individual antibody values for the FVO and 3D7 antigens are shown in [Table 2](#pone-0001563-t002){ref-type="table"}. Using all 34 subjects, there was high concordance between the log transformed antibody response to AMA1 FVO and AMA1 3D7 both before \[0.92 with 95% C.I. (0.85, 0.96) at Day 0\] and after vaccinations \[0.96 with 95% C.I. (0.93, 0.98) at Day 42\].

10.1371/journal.pone.0001563.t002

###### ELISA antibody values in plasma from volunteers on selected time points.

![](pone.0001563.t002){#pone-0001563-t002-2}

                                                   AMA1-FVO   AMA1-3D7                                                 
  ------------------------------------- --------- ---------- ---------- ------ ----- ------ ------ ------ ------ ----- ------
  1[\*](#nt101){ref-type="table-fn"}     Hiberix      14         14       63    14     35     32     14     40    14     73
  6                                                   14         14       14    14     14     14     14     14    14     14
  8                                                   14         14       14    14     14     14     14     14    14     14
  10                                                  14         14       14    14     14     14     14     14    14     14
  13                                                  14         14       14    14     70     14     14     14    14    157
  14                                                  33         33       14    14     14     58     47     14    14     14
  25                                                 365        263       84    14     14    305    215     78    14     14
  28                                                  14         14       14    14     85     36     29     14    14     80
  30                                                 257        249      199    450   167    123    115     88    175    74
  32                                                 1573       1175     663    362   419    2386   2340   1110   605   613
  33                                                 2416       1928     1175   471   451    2608   2084   1175   453   642
  2                                       20 µg       14         82      273    48     46     14    127    239    65     52
  3                                                   14         53      144    14    113     14     77    187    30     91
  4                                                   14        565      927    187   127     14    824    997    193   139
  5                                                   28        140      251    81     40     14    131    193    54     14
  7                                                   14        127      384    70     35     14    112    413    102    14
  9                                                   14         64      397    155    82     14    279    1188   492   252
  11                                                 2043       1480     1051   408   274    462    530    687    264   176
  12                                                  14         81      627    302   218     28    119    724    249   154
  15                                                  14         70      300    219   230     14    121    561    244   200
  16                                                 120        681      1427   325   174     52    425    1134   258   148
  17                                                  14         14      356    98     32     14     14    225    67     14
  18                                                  62        545      471    54     14     77    742    730    104    14
  19                                      80 µg       29         47      114    32     14     73    110    192    56     30
  20                                                  14         58      157    37     14     14     67    201    39     14
  22[\*](#nt101){ref-type="table-fn"}                 68        177      144    40    125     50    199    292    91    111
  23                                                  31         46      156    79    397     14     34    167    117   1009
  24[\*](#nt101){ref-type="table-fn"}                 14         34       14    14     14     14     14     14    14     14
  26                                                  14        245      530    167    93     68    958    1520   453   214
  27                                                  14         37      113    14     14     14    143    275    84     32
  29                                                  30         85      181    36     78     31     82    224    64     79
  31                                                 115        597      2640   454   146     49    268    1258   227    78
  34                                                  14        288      746    157   168     14    248    780    228   156
  35                                                  14        1983     3944   679   1200    29    2243   4348   674   1053

did not received the second vaccination due Hepatitis A.

For the test vaccine, an increase in the average of FVO and 3D7 responses was seen at Day 14 and continued to increase after the second vaccination (Day 42), but decreased by Days 98 and 154 ([Figure 2](#pone-0001563-g002){ref-type="fig"}). In the 20 µg group, the geometric mean antibody response (average FVO and 3D7) increased from 29.0 antibody units (95% CI 12--68.3) on Day 0 to 171.0 units (95% CI 76.6--372.3) on Day 14 and to 483 units (95% CI 319.7--729.7) on Day 42. Similarly, in the 80 µg dose group the mean antibody response increased from 27.5 units (95% CI 17.5--42.0) to 151.7 units (95% CI 62.7--367.4) and to 317.9 units (95% CI 113.1--893.9) on Day 42 while the corresponding mean antibody levels in the Hiberix® group were 73.1 units (95% CI 19.0--281.4), 63.8 units (95% CI 17.0--238.8) and 49.8 units (95% CI 15.8--157.3). The dose responses were significant at Days 14 and 42 (p values 0.0003, 0.0008, respectively).

![Average of FVO and 3D7 ELISA responses by Vaccine Day.\
Gray lines are individual subjects, black lines are geometric means within each randomization group.](pone.0001563.g002){#pone-0001563-g002}

Although there were still statistically significant dose responses at Days 98 (p = 0.0026) and 154 (p = 0.0170), by Day 98 the antibody responses in the 20 µg and 80 µg dose groups decreased to geometric mean levels about 3 times higher than those in subjects who received Hiberix®, with geometric means of 127.3 (95% CI 73.2--221.2) in the 20 µg dose group, 94.0 (95% CI 43.2--205.0) in the 80 µg dose and 35.2 (95% CI 12.2--102.0) in the Hiberix® group. These levels decreased further by Day 154.

Discussion {#s4}
==========

Interpretation {#s4a}
--------------

This Phase 1 study of AMA1-C1 adjuvanted with Alhydrogel at the dose of 20 and 80 µg in malaria exposed children in Mali showed that the vaccine was well tolerated, with no vaccine related severe or serious adverse event. This is consistent with the findings in two previous Phase 1 trials in malaria naïve and semi-immune adults [@pone.0001563-Malkin1], [@pone.0001563-Dicko1].

The vaccine induced antibodies to both constituent alleles, with responses to AMA1-FVO and AMA1-3D7 that were highly correlated, as seen in previous studies [@pone.0001563-Malkin1], [@pone.0001563-Dicko1]. Responses were seen 2 weeks after the first vaccination and further increased after the second vaccination. This is different from the study in malaria-naïve US adults [@pone.0001563-Malkin1], where no responses were seen after the first vaccination. This is likely due to prior malaria exposure, as shown by pre-existing antibody in 59% of subjects overall at baseline. Antibody responses after only one dose were also seen in semi-immune Malian adults [@pone.0001563-Dicko1]. However, compared to Malian adults, antibody levels were much lower overall both at baseline and after immunizations (geometric means of 1081.5 and 2634.9 units respectively at baseline and Day 42 in the 80 µg dose adult group) likely due to less prior exposure to malaria in children versus adults at this site [@pone.0001563-Dicko1]. While dose responses were significant at all time points tested, mean antibody levels for the 20 µg and 80 µg dose groups at Days 14 and 42 were similar, as shown by substantially overlapping confidence intervals.

In the US adult study with the same vaccine, as in other malaria vaccine studies in children [@pone.0001563-Bojang1], [@pone.0001563-Withers1], [@pone.0001563-Macete1], highest antibody responses were seen after the third dose of vaccine, and it is possible that a third dose is also needed in children in this endemic area, although in the Malian adult study with the same vaccine limited boosting was seen after the third dose [@pone.0001563-Dicko1]. Short half lives of IgG1 and IgG3 antibodies to merozoite antigens in children living in endemic areas have been reported in epidemiological studies in Mali [@pone.0001563-Fruh1] and in Kenya [@pone.0001563-Kinyanjui1]. In the Kenya study the mean half lives of IgG1 and IgG3 in children after severe malaria attack were 9.1 days (95% CI 7.6 and 12.0) and 6.1 days (95% CI 3.7--8.4 days) with little or no boosting after re-infection. Further studies are needed on the mechanisms of the immune response to merozoite antigens as well as the dynamics of these responses and their relationship to malaria infection and disease. Additionally, the ability of vaccination to induce a long term memory response should be further investigated.

Generalizability {#s4b}
----------------

This is the first Phase 1 study of an AMA 1 vaccine in children. It aimed to provide information on the safety and immunogenicity of this vaccine in this population in a malaria endemic area prior to a larger Phase 2b study. The study population was chosen to represent young children living in an area with seasonal intense malaria transmission and the results should be broadly generalizable to such populations. Like any Phase 1 study, it is powered to detect only frequent events or large differences. After reviewing the safety data in this study, a Phase 2 study was initiated. The Phase 2 study will provide further information on the safety and the immunogenicity of the AMA1-C1/Alhydrogel vaccine, as well as the biologic impact on parasitemia during the malaria transmission season. Although there is an increase in antibody in subjects who received the AMA1-C1 vaccine, the level of antibody that would lead to protection is unknown.

Overall evidence {#s4c}
----------------

This trial provided the first data on the safety and immunogenicity of AMA1--C1 vaccine in malaria exposed children. It shows that the vaccine is well tolerated and immunogenic although the duration of the induced antibody is short. The absence of safety concerns has justified a Phase 2b study. In addition to assessing biologic impact, the Phase 2b study will provide more information on both safety and immunogenicity as well as whether or not immunization during the transmission season leads to higher antibody responses to AMA1.
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